DMAC vs VICI · $157.4M cap vs P/E 9.3, rev $3.85B
DiaMedica Therapeutics Inc (DMAC) versus VICI Properties Inc (VICI) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
VICI Properties Inc (VICI) is a reit - diversified company listed on NYSE.
DMAC does not have a complete income-statement cache yet.
Latest reported VICI revenue for 2024-12-31 was $3.85B. Net income was $2.72B. Revenue was up 6.6% from 2023-12-31 to 2024-12-31. VICI currently screens at market cap $29.32B and trailing P/E 9.3.
DMAC currently screens at market cap $157.4M. VICI currently screens at market cap $29.32B and trailing P/E 9.3.
Not investment advice. Open the DMAC and VICI stock pages for the full models.
Not investment advice.